About Arcutis

Board of Directors

Back to All
Halley Gilbert, Board of Directors Member

Halley Gilbert, JD

Board Member

Ms Gilbert joined the Arcutis Board in May 2020. She brings significant experience in legal, corporate and business development, compliance, and government affairs. Ms. Gilbert was most recently Chief Legal Officer of NeoGenomics, Inc., a premier cancer diagnostic, pharma services and informatics company. Prior to NeoGenomics, Ms. Gilbert served as Chief Operating Officer of Adagio Therapeutics, Inc., a company focused on developing broadly neutralizing antibodies for the prevention and treatment of Covid-19 and future coronavirus outbreaks. In just over one year as an operating company, her contributions supported the seamless transition of Adagio to public company status, significant private financings, the advancement of the pipeline, and substantial team growth.

Previously, Ms. Gilbert spent 12 years in various roles of increasing scope and responsibility at Ironwood Pharmaceuticals, Inc. including, Senior Vice President of Corporate Development and Chief Administrative Officer, where she oversaw corporate and business development, legal, compliance and government affairs. Additionally, Ms. Gilbert served as Ironwood’s Senior Vice President, Chief Legal Officer and Corporate Secretary. Prior to joining Ironwood, she was Vice President, Deputy General Counsel at Cubist Pharmaceuticals, Inc. and served as a corporate counsel at Genzyme Corp., prior to its acquisition by Sanofi. She began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert currently serves on the boards of directors of CytomX Therapeutics and Vaxcyte, Inc. Previous board roles included Dermira, Inc., prior to its acquisition by Eli Lilly and Company, and Achaogen, Inc..

Ms. Gilbert holds a B.A. from Tufts University and a J.D. from Northwestern University School of Law.

Meaningful innovation at a glance.

Download our corporate fact sheet.